ClinicalTrials.gg
CompletedNCT03628534SERF VT EFSUpdated Aug 10, 2022

SERF VT Ablation Early Feasibility Study (EFS)

An interventional study of Saline Enhanced Radiofrequency (SERF) ablation in Ventricular Tachycardia, Arrythmia and Heart Diseases, sponsored by Thermedical, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-10.

Sponsored by Thermedical, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jun 2021, 5 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Tachycardia, Ventricular with a site in United States — 34 open to participants now, 40 under way, 2 of them phase 3. Tachycardia, Ventricular · United States.

Enrollment
79th of 107
16 · median 60
Started
2018
with 12 others
No phase
68 of 154
18 open now
Registered
86th of 154
by date

Among the 154 studies in Tachycardia, Ventricular with a site in United States, this one is the 79th largest by enrollment of the 107 interventional ones that give a count, is one of 13 that started in 2018, is one of 68 with no phase, and was the 86th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

34 of the 154 studies in Tachycardia, Ventricular with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Tachycardia, Ventricular with a site in United States, or all of them as a file.
02

Study summary

This is an early feasibility, non-randomized, open-label, single group, interventional study to be conducted in up to 20 US subjects to evaluate the technical feasibility of the Durablate Catheter and Thermedical Ablation System to eliminate or control sustained, monomorphic ventricular tachycardia (VT) in patients with VT refractory to drug and conventional catheter ablation with acceptable procedural safety.

Read the detailed description

The purpose of this study is to gather information on the technical feasiability and safety of a needle ablation catheter called the Durablate™ Saline Enhanced Radiofrequency (SERF) catheter. This catheter is being studied to treat ventricular tachycardia (VT) in patients who have already been treated with medicine, have an Implantable Cardioverter Defibrillator (ICD) and had an ablation procedure to treat their VT but continue to experience VT despite these treatments. A VT ablation procedure is done by finding the abnormal heart tissue that's causing the VT and applying energy with the tip of an ablation catheter to the area to create a scar or destroy the tissue that causes the VT. The SERF catheter being used in this study uses a needle to deliver heated saline (salt water) and radiofrequency energy deeper into the heart tissue that is causing the VT than a standard ablation catheter.

03

Conditions studied

  • Ventricular Tachycardia
  • Arrythmia
  • Heart Diseases
  • Cardiovascular Diseases

Keywords

  • Cardiac Arrhythmia
  • Ventricular Tachycardia
  • Arrhythmia
  • Pathological processes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has sustained, monomorphic VT
  2. Subject has recurrent, symptomatic VT
  3. Subject has drug or drug intolerant sustained VT following use of at least one Class III antiarrhythmic as demonstrated by a recurrent arrhythmia and is not a suitable candidate per the investigator's expert opinion for ongoing or alternative drug therapy
  4. and/or ICD evidence of a spontaneous VT recurrence within the prior 6 months that is suspected to be the same VT as initially targeted in a prior ablation
  5. Subject has minimum 3-month ICD interrogation history available for evaluation
  6. Subject has > 20%, confirmed by echo or comparable technique during baseline evaluation
  7. Subject is at least 18 years old
  8. Subject has signed the , and is willing and able to participate in all study procedures and follow up requirements

Exclusion criteria

EXCLUSION CRITERIA:

  1. Subjects with VT of idiopathic origin
  2. Subjects with VT with or MRI/CT findings suggestive of right ventricular free wall origin
  3. Subjects with VTs of septal origin require special care to minimize the risk of heart block, particularly within 2 cm of the AV node/proximal conduction system; Subjects requiring ablation at such locations should only be included when the arrhythmia itself is life-threatening or otherwise sufficiently severe to justify the risk
  4. Subject with myocardial infarction (MI) or unstable angina within previous 60 days
  5. Subject with cardiac surgery or percutaneous coronary intervention (PCI) within previous 60 days
  6. Subject with class IV () heart failure
  7. Subject with prosthetic cardiac valve(s), severe aortic stenosis or flail mitral valve
  8. Subject with left ventricular assist device planned or required for the procedure
  9. Subjects with co-morbidities such that they have less than 1-year
  10. Subject with evidence of intracardiac and/or laminated thrombus (in the left atrium including left atrial appendage or the left ventricle) evident by cardiac CT or transesophageal echo (TEE) and transthoracic echo (TTE) (with contrast if indicated) within 48 hours prior to ablation procedure
  11. Subject with thrombocytopenia or other coagulopathy
  12. Women who are or may potentially be pregnant (must be or have a negative pregnancy test)
  13. Subject with other acute illness or active systemic infection (unrelated to VT or its origin)
  14. Significant congenital heart disease or cardiac anomaly
  15. Allergy or to the medications/agents used during a standard ablation/EP intervention.
  16. Subject concurrently enrolled in any other drug or device study that the investigator deems would interfere with study results
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    single arm

    Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter

    Device: Saline Enhanced Radiofrequency (SERF) ablation

Interventions

  • DeviceSaline Enhanced Radiofrequency (SERF) ablation

    Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter

    Also known as: Durablate Catheter and Thermedical Ablation System

06

What researchers measure

Primary outcomes

  1. EFFICACY: Non-inducibility of the targeted clinical VT at end of ablation procedure.

    Completion of intended ablation during treatment setting as measured by non-inducibility of the targeted clinical VT (acute procedural success).

    Time frame: By the end of the procedure

  2. SAFETY: SAEs that are probably or definitely device related within 30 days

    Time frame: within 30 days

07

Study locations

3 sites
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Vanderbilt Heart
    Nashville, Tennessee 37232, United States
08

References and documents

Publications

  • Packer DL, Wilber DJ, Kapa S, Dyrda K, Nault I, Killu AM, Kanagasundram A, Richardson T, Stevenson W, Verma A, Curley M; SERF Investigators. Ablation of Refractory Ventricular Tachycardia Using Intramyocardial Needle Delivered Heated Saline-Enhanced Radiofrequency Energy: A First-in-Man Feasibility Trial. Circ Arrhythm Electrophysiol. 2022 Aug;15(8):e010347. doi: 10.1161/CIRCEP.121.010347. Epub 2022 Jul 1. PubMed 35776711 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jun 2021, 31 months.

Of 40 industry-sponsored interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 52. This study's 31 months is close to that.

Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2018
First posted
Aug 14, 2018
StartActual
Nov 1, 2018
Primary completionActual
Jun 30, 2021
CompletionActual
Jul 31, 2022
Last update
Aug 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03628534
Lead sponsor
Thermedical, Inc.
Responsible party
Sponsor
First posted
Aug 14, 2018
Start date
Nov 1, 2018
Primary completion
Jun 30, 2021
Completion
Jul 31, 2022
Last update
Aug 10, 2022

Study contacts

Douglas Packer, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion